Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma.
Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma.
复制标题
DOI：
10.1007/s12325-016-0461-z
复制
发表时间：
2017-02
影响因子：
3.8
通讯作者：
Konstas AG
中科院分区：
文献类型：
--
作者：
Andrés-Guerrero V;Perucho-González L;García-Feijoo J;Morales-Fernández L;Saenz-Francés F;Herrero-Vanrell R;Júlvez LP;Llorens VP;Martínez-de-la-Casa JM;Konstas AG
十年前，首批抗血管内皮生长因子 (VEGF) 药物之一被批准用于治疗新生血管性年龄相关性黄斑变性，这标志着几种威胁视力的视网膜疾病治疗新时代的开始。此后，不断出现的证据证明这些疗法可用于治疗其他以 VEGF 水平升高为特征的眼部疾病。在本文中，我们回顾了目前使用抗 VEGF 药物作为辅助治疗治疗新生血管性青光眼 (NVG) 的观点。还回顾了在青光眼滤过手术 (GFS) 中使用抗 VEGF 来改变伤口愈合。调查抗 VEGF 药物或抗代谢药物在 GFS 或 NVG 治疗中的使用的选定研究表明，这些药物可以改善手术结果。然而，与当今常用的更成熟的药物相比，抗 VEGF 药物尚未表现出具体的优势。需要进一步的研究来评估这些治疗的作用持续时间、给药间隔和毒性特征。
The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments.